JP2019526544A - ５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法 - Google Patents

５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法 Download PDF

Info

Publication number
JP2019526544A
JP2019526544A JP2019506431A JP2019506431A JP2019526544A JP 2019526544 A JP2019526544 A JP 2019526544A JP 2019506431 A JP2019506431 A JP 2019506431A JP 2019506431 A JP2019506431 A JP 2019506431A JP 2019526544 A JP2019526544 A JP 2019526544A
Authority
JP
Japan
Prior art keywords
fenfluramine
drug
inhibitor
formulation
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019506431A
Other languages
English (en)
Japanese (ja)
Inventor
スティーブン ジェイ． ファー
スティーブン ジェイ． ファー
ブルックス ボイド
ブルックス ボイド
Original Assignee
ゾゲニクス インターナショナル リミテッド
ゾゲニクス インターナショナル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59955585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019526544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ゾゲニクス インターナショナル リミテッド, ゾゲニクス インターナショナル リミテッド filed Critical ゾゲニクス インターナショナル リミテッド
Publication of JP2019526544A publication Critical patent/JP2019526544A/ja
Priority to JP2022146769A priority Critical patent/JP2022180461A/ja
Priority to JP2024176867A priority patent/JP2024180450A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019506431A 2016-08-24 2017-08-02 ５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法 Withdrawn JP2019526544A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022146769A JP2022180461A (ja) 2016-08-24 2022-09-15 ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
JP2024176867A JP2024180450A (ja) 2016-08-24 2024-10-09 ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379183P 2016-08-24 2016-08-24
US62/379,183 2016-08-24
US201762515383P 2017-06-05 2017-06-05
US62/515,383 2017-06-05
PCT/IB2017/054740 WO2018037306A1 (en) 2016-08-24 2017-08-02 Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022146769A Division JP2022180461A (ja) 2016-08-24 2022-09-15 ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法

Publications (1)

Publication Number Publication Date
JP2019526544A true JP2019526544A (ja) 2019-09-19

Family

ID=59955585

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019506431A Withdrawn JP2019526544A (ja) 2016-08-24 2017-08-02 ５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
JP2022146769A Pending JP2022180461A (ja) 2016-08-24 2022-09-15 ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
JP2024176867A Pending JP2024180450A (ja) 2016-08-24 2024-10-09 ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022146769A Pending JP2022180461A (ja) 2016-08-24 2022-09-15 ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
JP2024176867A Pending JP2024180450A (ja) 2016-08-24 2024-10-09 ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法

Country Status (15)

Country Link
US (6) US20180055789A1 (enExample)
EP (2) EP4201427A1 (enExample)
JP (3) JP2019526544A (enExample)
KR (3) KR20250040753A (enExample)
CN (2) CN109689103A (enExample)
AU (3) AU2017315273B2 (enExample)
CA (1) CA3032996C (enExample)
ES (1) ES3029536T3 (enExample)
IL (2) IL290727B2 (enExample)
MX (2) MX2019001799A (enExample)
RU (2) RU2021106383A (enExample)
SG (1) SG11201900975XA (enExample)
TW (3) TWI776407B (enExample)
WO (1) WO2018037306A1 (enExample)
ZA (1) ZA201900766B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022180461A (ja) * 2016-08-24 2022-12-06 ゾゲニクス インターナショナル リミテッド ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
MX391077B (es) 2015-12-22 2025-03-21 Zogenix International Ltd Composiciones de fenfluramina y métodos de preparación de las mismas.
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
CN111867822B (zh) 2018-06-15 2022-06-10 株式会社Lg化学 装饰构件
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
WO2020112460A1 (en) * 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
CN114585354A (zh) 2019-09-17 2022-06-03 周格尼克斯国际有限公司 用芬氟拉明治疗癫痫患者的方法
CN115003289B (zh) * 2019-11-21 2025-01-10 新凯治疗有限公司 大麻二酚和/或考比司他联合药物疗法
TW202200152A (zh) * 2020-04-30 2022-01-01 泰合生技藥品股份有限公司 氯巴占(clobazam)經皮傳遞系統及其用途
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023101866A1 (en) * 2021-12-01 2023-06-08 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2025174742A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated Concomitant administration of miricorilant with cyp2c19 inhibitors
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518387A (ja) * 2013-05-03 2016-06-23 カトリック ユニバーシテイト ルーベン ドラベ症候群の処置における使用のためのフェンフルラミン

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (enExample) 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
DE3717434C1 (de) 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
KR890003368A (ko) 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2663539B1 (fr) * 1990-06-22 1994-10-07 Adir Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age.
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
FR2685204B1 (fr) * 1991-12-19 1995-06-16 Palmer Research Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
DE69422044T2 (de) 1993-08-06 2000-05-31 Pharmacia & Upjohn Co., Kalamazoo 2-aminoindane als selektive dopamin-d3-liganden
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
EP0762877B1 (en) 1994-06-03 2001-03-21 THEJMDE Trust Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
IT1298349B1 (it) 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
EP1140061B1 (en) 1998-12-23 2003-05-02 Orphan Medical Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
AU2001275095A1 (en) 2000-07-17 2002-01-30 Opt-E-Scrip, Inc. Single-patient drug trials used with accumulated database
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
ES2339339T3 (es) 2001-06-22 2010-05-19 Universite Catholique De Louvain Perlas o capsulas de hidrogel como medios artificiales para la oviposicion de insectos y la cria de endoparasitoides.
CA2455939C (en) 2001-07-31 2011-03-22 Wyeth Llc Sucralose formulations to mask unpleasant tastes
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
RU2317104C2 (ru) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
US20060079582A1 (en) 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
EP1863381A4 (en) 2005-03-21 2009-09-09 Health Smart Ltd SYSTEM FOR CONTINUOUS BLOOD PRESSURE MONITORING
WO2006125774A1 (en) 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
CA2612180A1 (en) 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
US9125900B2 (en) 2005-09-14 2015-09-08 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
CA2622967A1 (en) 2005-09-19 2007-03-29 Biolert Ltd. A system and method for detecting an epileptic event
CA2630604C (en) 2005-11-29 2016-01-19 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
CN101365435A (zh) 2006-02-06 2009-02-11 诺瓦提斯公司 有机化合物的组合产品
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
US8039468B2 (en) 2006-08-31 2011-10-18 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
EP2066664A1 (en) * 2006-09-22 2009-06-10 Novartis AG Heterocyclic organic compounds
WO2008095072A2 (en) 2007-01-31 2008-08-07 Quintiles Transnational Corp. Methods and systems for site startup
HRP20161233T1 (hr) 2007-02-08 2016-12-02 Biogen Ma Inc. Neurozaštita u demijelinizirajućim bolestima
JP2010520162A (ja) 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
EP2254577A1 (en) * 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
CN102170874A (zh) 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
PE20142357A1 (es) * 2008-09-05 2015-02-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
BRPI0919796A2 (pt) 2008-10-09 2015-12-15 Acraf formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitável
EP2355818A4 (en) 2008-10-10 2012-04-11 Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res METHOD AND COMPOSITIONS FOR TREATING THE STATUS EPILEPTICUS AND STATUS EPILEPTICUS CAUSING ATTACHMENTS
TWI503101B (zh) 2008-12-15 2015-10-11 Proteus Digital Health Inc 與身體有關的接收器及其方法
EP2406765A4 (en) 2009-03-09 2014-12-31 Celgene Corp DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
US20100324936A1 (en) 2009-04-22 2010-12-23 Suresh-Kumar Venkata Vishnubhatla Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
UY33173A (enExample) 2010-01-08 2011-07-29 Eurand Inc
AU2011224520B2 (en) 2010-03-09 2016-04-21 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
EP2571858B1 (en) 2010-05-21 2018-06-20 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
EP2598159A4 (en) * 2010-07-30 2014-01-08 Merck Sharp & Dohme INHIBITION OF THE CYP3A DRUG MIXTURE EXCHANGE
CA3050049A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
JP2013540807A (ja) 2010-10-26 2013-11-07 アルファーマ ファーマシューティカルズ エルエルシー オピオイド過量投与によって誘発される呼吸抑制を減弱する製剤および方法
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US10183008B2 (en) * 2011-02-09 2019-01-22 University Of South Carolina Treatment of prolonged status epilepticus
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
EP2806867A4 (en) 2012-01-27 2015-09-02 Catalyst Pharmaceutical Partners Inc METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
DE102012213040B4 (de) * 2012-07-25 2014-03-20 Infineon Technologies Ag Decoder für physikalisch nicht klonbare Funktionen mittels Schwellendekodierung und entsprechendes Verfahren
SG11201503505QA (en) 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
HRP20201002T1 (hr) 2013-07-25 2020-10-16 Neuren Pharmaceuticals Limited Neuroprotektivni biciklički spojevi i metode za njihovo korištenje u tretmanu poremećaja autističnog spektra i neurorazvojnih poremećaja
HRP20201302T1 (hr) 2013-08-19 2021-02-05 The Regents Of The University Of California Spojevi i metode za liječenje epileptičnog poremećaja
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20150141415A1 (en) 2013-11-20 2015-05-21 Omonike Arike Olaleye Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
JP6147676B2 (ja) * 2014-01-07 2017-06-14 東芝テック株式会社 情報処理装置、店舗システム及びプログラム
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
JP6188929B2 (ja) 2014-04-22 2017-08-30 国立大学法人東北大学 肺高血圧症の検査方法
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
US10849518B2 (en) 2014-06-30 2020-12-01 University Of Cincinnati Non-invasive detection of spreading depolarization using scalp electroencephalography
US10452815B2 (en) 2014-09-29 2019-10-22 Zogenix International Limited Control system for control of distribution of medication
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CN115487313A (zh) 2015-02-06 2022-12-20 马瑞纳斯制药公司 静脉内加奈索酮制剂及其用途
KR102385665B1 (ko) 2015-02-25 2022-04-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 질환을 치료하기 위한 5ht 작용제
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
CN104800168A (zh) * 2015-04-08 2015-07-29 石家庄四药有限公司 司替戊醇干混悬剂及其制备方法
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
SMT201900571T1 (it) 2015-06-17 2019-11-13 Univ Columbia Terapia con deossinucleosidi per malattie causate da pool di nucleotidi sbilanciati tra cui le sindromi da deplezione del dna mitocondriale
NO346258B1 (en) 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
US10004749B2 (en) 2015-07-22 2018-06-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
HUE066912T2 (hu) 2015-08-24 2024-09-28 Zogenix International Ltd Lennox-Gastaut szindróma kezelési eljárása fenfluramin alkalmazásával
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
MX391077B (es) 2015-12-22 2025-03-21 Zogenix International Ltd Composiciones de fenfluramina y métodos de preparación de las mismas.
CN108699312B (zh) 2016-01-14 2021-04-20 Ａｇｃ株式会社 含氟树脂溶液、含氟树脂溶液的制造方法、涂料组合物及涂装物品
CN109069510A (zh) 2016-03-28 2018-12-21 武田药品工业株式会社 药物
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
MX2019009292A (es) 2017-02-08 2019-09-13 Ovid Therapeutics Inc Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi.
JP2020519594A (ja) 2017-05-09 2020-07-02 ゾゲニクス インターナショナル リミテッド フェンフルラミンを用いるドゥーゼ症候群の治療方法
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
US20190125697A1 (en) 2017-09-26 2019-05-02 Zogenix International Limited Method of reduction in convulsive seizure frequency
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
KR20210009317A (ko) 2018-04-18 2021-01-26 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 미토콘드리아 dna 고갈 증후군을 포함하는 불균형 뉴클레오타이드 풀에 의해 초래된 질환에 대한 유전자 요법
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EP3820459A1 (en) 2018-07-10 2021-05-19 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
PE20211065A1 (es) 2018-07-27 2021-06-09 Xenon Pharmaceuticals Inc Metodo para tratar la epilepsia
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
WO2020112460A1 (en) 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
WO2020176276A1 (en) 2019-02-25 2020-09-03 Zogenix International Limited A formulation for improving seizure control
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
EP4395753A4 (en) 2021-09-01 2025-05-07 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518387A (ja) * 2013-05-03 2016-06-23 カトリック ユニバーシテイト ルーベン ドラベ症候群の処置における使用のためのフェンフルラミン

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EPILEPTIC. DISORD., 2014, VOL.16, NO.4, PP.409-432, JPN6021025198, ISSN: 0004771740 *
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, VOL.57, NO. 1, PP.11-19, JPN6021025195, ISSN: 0004544827 *
ONFI PRESCRIBING INFORMATION. LUNDBECK, DEERFIELD, REFERENCE ID: 4028780 [ONLINE], 2016年12月，[2021, JPN6021025197, ISSN: 0004771741 *
PHARMACOGENETICS, 1998, VOL.8, PP.423-432, JPN6021025200, ISSN: 0004771739 *
SEMIN. PEDIATR. NEUROL., 2016.6, VOL.23, PP.167-179, JPN6021025196, ISSN: 0004544826 *
STUDY NCT02926898 ON DATE: MAY 1, 2017 (V6)，CLINICALTRIALS.GOV ARCHIVE[ONLINE]，2017年5月1日，[2021, JPN6021025202, ISSN: 0004771738 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022180461A (ja) * 2016-08-24 2022-12-06 ゾゲニクス インターナショナル リミテッド ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法

Also Published As

Publication number Publication date
TW202308601A (zh) 2023-03-01
US20180055789A1 (en) 2018-03-01
EP3518975A1 (en) 2019-08-07
US11406606B2 (en) 2022-08-09
NZ750691A (en) 2021-06-25
US20200246281A1 (en) 2020-08-06
CN109689103A (zh) 2019-04-26
AU2017315273B2 (en) 2021-04-29
IL290727B1 (en) 2023-08-01
RU2019105059A (ru) 2020-09-25
TW202432093A (zh) 2024-08-16
US11040018B2 (en) 2021-06-22
KR20190040237A (ko) 2019-04-17
CN120241681A (zh) 2025-07-04
MX2023005140A (es) 2023-05-26
US10603290B2 (en) 2020-03-31
US20220125743A1 (en) 2022-04-28
SG11201900975XA (en) 2019-03-28
JP2022180461A (ja) 2022-12-06
JP2024180450A (ja) 2024-12-26
KR20250040753A (ko) 2025-03-24
RU2021106383A (ru) 2021-04-05
KR20230021172A (ko) 2023-02-13
TWI722233B (zh) 2021-03-21
TW202131908A (zh) 2021-09-01
CA3032996A1 (en) 2018-03-01
EP4201427A1 (en) 2023-06-28
CA3032996C (en) 2025-05-06
AU2022279469A1 (en) 2023-02-02
ZA201900766B (en) 2020-10-28
US11786487B2 (en) 2023-10-17
EP3518975B1 (en) 2025-04-09
TWI776407B (zh) 2022-09-01
MX2019001799A (es) 2019-06-13
US20210393550A1 (en) 2021-12-23
AU2021204250A1 (en) 2021-07-22
AU2021204250B2 (en) 2022-09-01
ES3029536T3 (en) 2025-06-24
IL264637B (en) 2022-04-01
US20210267916A1 (en) 2021-09-02
AU2017315273A1 (en) 2019-03-07
US20190083424A1 (en) 2019-03-21
TW201821071A (zh) 2018-06-16
IL290727B2 (en) 2023-12-01
RU2746000C2 (ru) 2021-04-05
AU2022279469B2 (en) 2024-05-02
US11759440B2 (en) 2023-09-19
RU2019105059A3 (enExample) 2020-11-25
WO2018037306A1 (en) 2018-03-01
IL290727A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
AU2022279469B2 (en) Formulation for inhibiting formation of 5-HT 2b agonists and methods of using same
US20190083425A1 (en) Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
IL293907A (en) Treatment of amyotrophic lateral sclerosis and related disorders
JP2023075247A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
WO2020092618A1 (en) Methods of treating depression, anxiety and sexual dysfunction using the compound primavanserin
TW202339763A (zh) 用於治療多種疾病之組成物及方法
HK40012506A (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
HK40012506B (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
NZ750691B2 (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
HK40007948A (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190521

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200703

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220516

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220916

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240604